The World Health Organization is pausing the use of hydroxychloroquine in its global study of COVID-19 treatments amid a review of safety data, officials announced Monday.
周一，世界衛(wèi)生組織官員宣布，審查安全數(shù)據(jù)期間，在對(duì)新冠病毒療法的全球研究中暫停使用羥氯喹。

The move follows findings from a large observational study, published Friday, that found increased risk of heart problems and death in COVID-19 patients who used chloroquine and hydroxychloroquine.
此前，在周五發(fā)表的一項(xiàng)大型觀察性研究中發(fā)現(xiàn)，使用氯喹和羥氯喹的新冠病人患心臟病和死亡的風(fēng)險(xiǎn)會(huì)增加，因此做出這一決定。

It’s a scientific decision nonetheless fraught with politics: U.S. President Donald Trump is a champion of hydroxychloroquine, revealing last week that he’s taking it to prevent COVID-19. He has threatened to cut off U.S. funding to the WHO within a month absent unspecified reforms.
盡管如此，但這一科學(xué)決定充滿政治因素：美國(guó)總統(tǒng)唐納德·特朗普支持羥氯喹，他上周說(shuō)正在吃羥氯喹來(lái)預(yù)防感染新冠病毒。他威脅說(shuō)，如果不進(jìn)行具體改革，將在一個(gè)月內(nèi)切斷美國(guó)對(duì)世界衛(wèi)生組織的資金支持。

The executive committee of the WHO’s Solidarity trial met last Saturday, said WHO Chief Scientist Soumya Swaminathan, and decided “in the light of this uncertainty that we should be proactive, err on the side of caution and suspend enrollment temporarily into the hydroxychloroquine arm.” (Chloroquine is not part of the trial.)
世界衛(wèi)生組織首席科學(xué)家Soumya Swaminathan說(shuō)，世界衛(wèi)生組織的SOLIDARITY臨床試驗(yàn)執(zhí)行委員會(huì)上周召開(kāi)會(huì)議，決定“鑒于這種不確定性，我們要有前瞻性，謹(jǐn)慎行事，暫停使用羥氯喹”。（氯喹并不是此次試驗(yàn)用藥。）

The meeting came a day after the Lancet published the largest observational study of the malaria drugs to date, and as some national regulators began expressing concern about using the drug.
會(huì)議召開(kāi)前一天，《柳葉刀》發(fā)表了迄今針對(duì)瘧疾藥物最大的觀察性研究，一些國(guó)家監(jiān)管機(jī)構(gòu)開(kāi)始表現(xiàn)出對(duì)使用這種藥物的擔(dān)憂。

WHO officials estimated the pause would last a week or two as the trial’s data safety monitoring board considers information already collected from the Solidarity trial and other ongoing studies to determine whether it’s safe to continue with hydroxychloroquine.
世界衛(wèi)生組織官員估計(jì)暫停會(huì)持續(xù)一至兩周，因?yàn)樵囼?yàn)數(shù)據(jù)安全監(jiān)測(cè)委員會(huì)要參考從SOLIDARITY臨床試驗(yàn)和其他進(jìn)行中的研究中所收集的信息，從而確定繼續(xù)使用羥氯喹是否安全。

The study, a randomized trial, has enrolled 3,500 patients in at least 17 countries since March to study four medicines, including hydroxychloroquine.
這項(xiàng)研究是隨機(jī)試驗(yàn)，從三月份開(kāi)始在至少17個(gè)國(guó)家召集了3,500名患者來(lái)研究4種藥物，其中就包括羥氯喹。

?

翻譯：菲菲